Compare First Citizens BancShares Inc (FCNCA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs GeneDx Holdings Corp — how do they compare? First Citizens BancShares Inc trades at $2,068.39 (market cap $22.94B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: First Citizens BancShares Inc is far larger — about 11.4× GeneDx Holdings Corp's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and GeneDx Holdings Corp for 19 Days on average.
| FCNCA | WGS | |
|---|---|---|
Market Cap | $22.94B | $2.02B |
Volume | 91,668 | 734,640 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $167.51 |
52-Week Low | $1.64K | $34.51 |
Typical Hold Time | 29 Days | 19 Days |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,065.89, down slightly (-0.27%) with a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats (Q2 2026 EPS of $57.09 vs. $40.69 expected) and robust profitability (25.23% net margin). Recent developments include branch expansions and significant commercial lending activity, though cash flow trends show heavy investment outflows. Analyst sentiment is cautious with 82% hold ratings despite a $2,290 consensus price target suggesting modest upside potential.
FCNCA presents a mixed investment case with solid fundamentals offset by technical weakness and cautious analyst sentiment. The stock offers value characteristics with an 11.08 P/E ratio and dividend income, but faces headwinds from bearish technical indicators and institutional selling pressure. Key risks include execution of expansion strategy and potential margin compression in a competitive banking environment.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
